Martin Edwards M.D., MBA
Martin Edwards, M.D. has served on our board of directors since September 2017. Dr. Edwards is employed on a part-time basis as a senior partner at Novo Holdings A/S, a Danish limited liability company that manages investments and financial assets. He has been employed as a partner or more recently senior partner by Novo Ventures or Novo Holdings A/S since 2003. Dr. Edwards is expected to retire from Novo Holdings A/S in the fall of 2020. Dr. Edwards served as a partner at Novo Holdings A/S from 2003 to 2009. Earlier in his career, Dr. Edwards served as chief executive officer of ReNeuron Ltd., a stem cell research company based in the United Kingdom, and as global head of drug development for Novo Nordisk A/S, where he led preclinical and clinical drug development. Dr. Edwards currently serves on the board of directors of KalVista Pharmaceuticals, Inc. and Verona Pharma plc, both publicly traded pharmaceutical companies, and previously served on the board of directors of CoLucid Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from January 2015 to March 2017. Dr. Edwards received an M.B.A. from the University of Warwick in England and an M.D. from the University of Manchester in England.